Affimed NV
NASDAQ:AFMD

  • LAST PRICE
    3.0000
  • TODAY'S CHANGE (%)
    -0.1600 (-5.0633%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    3.1900 / 3.1600
  • Day Range
    2.9000
    3.1900
  • 52 Week Range
    2.9000
    8.9500
  • Volume
    240,547

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AFMD
Affimed NV
48.1M
-0.6x
---
CLGN
Collplant Biotechnologies Ltd
47.5M
-2.7x
---
ATRA
Atara Biotherapeutics Inc
64.2M
-0.4x
---
KRON
Kronos Bio Inc
51.2M
-0.6x
---
LVTX
LAVA Therapeutics NV
42.9M
-1.7x
---
CRIS
Curis Inc
31.6M
-0.5x
---
As of 2024-11-20

Company Information

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Contact Information

Headquarters
Im Neuenheimer Feld 582HEIDELBERG, Germany 69120
Phone
---
Fax
---

Executives

Independent Chairman of the Supervisory Board
Thomas Hecht
Chief Executive Officer, Member of the Management Board
Shawn Leland
Consulting Chief Financial Officer, Member of the Management Board
Harry Welten
Chief Operating Officer, Member of the Management Board
Wolfgang Fischer
Chief Medical Officer, Member of the Management Board
Andreas Harstrick

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$45.7M
Revenue (TTM)
$929.2K
Shares Outstanding
15.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.10
EPS
$-4.84
Book Value
$4.10
P/E Ratio
-0.6x
Price/Sales (TTM)
49.2
Price/Cash Flow (TTM)
---
Operating Margin
-8,005.25%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.